蛋白质组学技术的合理运用于食管癌治疗的双盲性临床价值  

The Research and Discussion on the Double Blind Clinical Value of the Treatment of Esophageal Cancer with the Reasonable Application of Proteomics Technology

作　　者：杨宏[1] 周俊[1] 郝婷婷[1] 刘修莉[1] 

机构地区：[1]三峡大学人民医院,湖北省宜昌市第一人民医院,443000

出　　处：《实用癌症杂志》2018年第1期20-22,26,共4页The Practical Journal of Cancer

摘　　要：目的探索蛋白质组学技术应用于食管癌的各期治疗和提供治疗后评价的临床价值。方法采用随机双盲的研究方法。33例确诊为食管癌,被随机分为2组,试验组22例,对照组11例。试验组静脉滴注西妥昔单抗,对照组静脉滴注顺铂,2组疗程均为3周。治疗前后使用模拟CT和食管钡餐正侧位点片测定2组病灶直径长度,检测鳞状上皮癌相关抗原(SCC)和细胞角化素蛋白片段19(CYFRA21-1)于患者体内的血清浓度。结果试验组和对照组的肿瘤直径均有不同程度的减少,缓解率试验组67.3%,高于对照组58.6%。SCC治疗后均值实验组(0.78±0.33)μg/L,显著低于对照组(0.95±0.42)μg/L;CYFPRA21-1治疗后均值实验组(1.78±1.02)μg/L,显著低于对照组(2.43±1.48)μg/L,差异均具有统计学意义(P均<0.05)。结论蛋白质组学技术应用于食管癌的各期治疗效果良好,并能提供良好的预后评价指标,在临床值得推广和借鉴。Objective To explore the clinical value of proteomics techniques in the treatment of esophageal cancer and to provide the evaluation of the treatment. Methods A randomized, double blind,research method was used. 33 cases of esopha- geal cancer were randomly divided into 2 groups,22 cases in the experimental group, 11 cases in the control group, the experimen- tal group received intravenous infusion of cetuximab, the control group received intravenous infusion of cisplatin, the 2 groups were treated for 3 weeks,to evaluate the 2 groups before and after treatment with simulated CT and esophageal barium meal side site tablets determination of the diameter of lesion length, detection of squamous cell carcinoma associated antigen（SCC） and keratino- cyte protein fragment 19 （CYFRA21-1） serum concentration in the patients. Results The experimental group and the control group reduced the tumor diameter in varying degrees, the remission rate of the experimental group was 67.3 %, which was higher than the control group,5g. 6% ,the average SCC after treatment of the experimental group was （0.7±0. 33 ） μg/L,which was lower than the control group, （0.95 ± 0.42） μg/L, after treatment average CYFRA21-1 of the experimental group was （ 1.78 ± 1.02） μg/L, which was lower than the control group, （2.43 ± 1.48 ）μg/L,P 〈 0.05, the difference was statistically significant. Conclusion proteomics technology in the treatment of esophageal cancer patients with good results and can provide a good prog- nostic evaluation index, in the clinical value of the promotion and reference.

关 键 词：蛋白质组学技术 SCC CYFRA21-1 评价指标 

分 类 号：R735.1[医药卫生—肿瘤]